Semaglutide
→Insulin

12

2

2

↑12

↓2

—2

Evidence suggests Semaglutide mayincreaseInsulin.

11 studies (16 claims)

Moderate consensus

Study Claims

14 of 16

Intervention	Direction	Endpoint	Type	Population	Dosage	Title
semaglutide 1 mg	No effect - did not change substantially	estimated hepatic insulin-to-glucagon ratio	Human	patients with type 2 diabetes treated with metformin	—	Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.
semaglutide	Increases - significantly higher	fasting insulin	Animal	obese type 2 diabetic db/db mice	—	Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.
semaglutide	Increases - increased	quality of insulin granules in β-cells	Animal	obese type 2 diabetic db/db mice	—	Tirzepatide, a dual glucose-dependent insulinotropic polypeptide/glucagon-like peptide 1 receptor agonist, exhibits favourable effects on pancreatic β-cells and hepatic steatosis in obese type 2 diabetic db/db mice.
semaglutide	Increases - significantly increased	first-phase insulin secretion	Human	participants with type 2 diabetes	—	Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
semaglutide	Increases - significantly increased	insulin AUC	Human	participants with type 2 diabetes	—	Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
semaglutide	Increases - significantly increased	second-phase insulin secretion	Human	participants with type 2 diabetes	—	Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.
semaglutide	Decreases - reduced	insulin requirements	Human	adult with CFRD, obesity, and clinical insulin resistance	—	Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.
semaglutide	Decreases - reduced	total daily insulin dose	Human	adult with CFRD, obesity, and clinical insulin resistance	—	Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.
semaglutide	No effect	insulin requirements	Human	patients with type 2 diabetes who were also on insulin	—	Evaluation of Insulin Dosage After the Addition of Tirzepatide Compared With Semaglutide or Dulaglutide in Patients With Type 2 Diabetes.
semaglutide (Ozempic and Wegovy)	Increases - enhance	insulin secretion	Animal	—	—	Long-acting hydrogel-based depot formulations of tirzepatide and semaglutide for the management of type 2 diabetes and weight.
semaglutide (Ozempic and Wegovy)	Increases - enhance	insulin sensitivity	Animal	—	—	Long-acting hydrogel-based depot formulations of tirzepatide and semaglutide for the management of type 2 diabetes and weight.
semaglutide	Increases - enhanced	insulin sensitivity	Animal	male C57BL/6J mice fed a high-fat, high-fructose diet	—	Distinct effects of semaglutide and tirzepatide on metabolic and inflammatory gene expression in brown adipose tissue of mice fed a high-fat, high-fructose diet.
Semaglutide	Increases - increases	production of insulin	Human	—	—	Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity.
combining 1 mM metformin with 10 nM semaglutide	Increases - demonstrated superior restoration	glucose-stimulated insulin secretion (GSIS) functionality	Molecular	INS-1 β-cells	—	Single and Combined Impact of Semaglutide, Tirzepatide, and Metformin on β-Cell Maintenance and Function Under High-Glucose-High-Lipid Conditions: A Comparative Study.